Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.62 |
| ▸ | RXRA | P19793 | 2/20 | 0.60 |
| ▸ | RXRB | P28702 | 2/20 | 0.60 |
| ▸ | RXRG | P48443 | 2/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11768921 | 0.99 | LRRK2 (0.61) | LRRK2FOLH1RXRARXRBRXRG | |
| SCHEMBL11768928 | 0.90 | LRRK2 (0.61) | LRRK2FOLH1RXRARXRBRXRG | |
| SCHEMBL17141476 | 0.89 | LRRK2 (0.58) | LRRK2FOLH1RXRARXRBRXRG | |
| SCHEMBL3995545 | 0.89 | PTPN1 (0.58) | LRRK2FOLH1RXRARXRBRXRG | |
| SCHEMBL1647092 | 0.89 | LRRK2 (0.65) | LRRK2FOLH1RXRARXRBRXRG | |
| SCHEMBL4721826 | 0.89 | LRRK2 (0.64) | LRRK2RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL28544263 | 0.89 | RXRA (0.60) | LRRK2FOLH1RXRARXRBRXRG | |
| SCHEMBL3991789 | 0.85 | PTPN1 (0.58) | LRRK2FOLH1RXRARXRBRXRG | |
| SCHEMBL2451483 | 0.84 | RXRA (0.58) | FOLH1RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL5465981 | 0.83 | LRRK2 (0.55) | LRRK2RXRARXRBRXRGMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1874776-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| CN-1860113-A | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER (US) | 2006-11-08 | — | — | CN | disclosed |
| WO-2006114274-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| CN-1829712-A | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER (US) | 2006-09-06 | — | — | CN | disclosed |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | BARBER CHRISTOPHER G | 2006-08-10 | — | — | US | disclosed |
| EP-1651641-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651640-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2005009994-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009995-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020611-A1 | Compounds | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| US-4146631-A | ANTIALLERGENS, RESPIRATORY DISORDERS | MAY & BAKER LIMITED (GB) | 1979-03-27 | — | — | US | disclosed |
| US-3953595-A | Substituted benzoic acid hypolipemic agents | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020611-A1 | Compounds | NQO1, NAMPT, NNT | LRRK2 2781/4885FOLH1 1820/4885RXRA 344/4885 |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | PTGER1, PTGER2, PTGER4 | LRRK2 3987/4885FOLH1 4507/4885RXRA 65/4885 |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | PDE4A, PDE4B, PDE4C | LRRK2 3240/4885FOLH1 1273/4885RXRA 766/4885 |
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | LRRK2 2781/4885FOLH1 1820/4885RXRA 344/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | LRRK2 2781/4885FOLH1 1820/4885RXRA 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.